Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 8,857 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares in the company, valued at $477,200.20. This trade represents a 55.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Cortney Caudill also recently made the following trade(s):

• On Monday, March 9th, Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.80, for a total value of $1,356,000.00.

Halozyme Therapeutics Stock Down 0.5%

Shares of HALO opened at $67.81 on Wednesday. The firm has a market cap of $8.00 billion, a P/E ratio of 27.23, a PEG ratio of 0.28 and a beta of 0.98. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The stock’s 50 day moving average is $72.64 and its two-hundred day moving average is $70.67. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. During the same period in the previous year, the company earned $1.26 earnings per share. The company’s quarterly revenue was up 51.6% compared to the same quarter last year. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics during the third quarter worth approximately $25,000. Measured Wealth Private Client Group LLC grew its holdings in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Richardson Financial Services Inc. increased its stake in shares of Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 198 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $32,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Benchmark lifted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $78.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.